Fresh from the No­var­tis/Trump scan­dal, ex-CEO Joe Jimenez jumps on the board of uBio­me — a biotech launch­ing an R&D group

Af­ter fig­ur­ing in as one of the cen­tral fig­ures for one of the most talked about scan­dals in bio­phar­ma his­to­ry, ex-No­var­tis CEO Joe Jimenez is step­ping back out on­to the stage to­day with a board seat at a com­mer­cial mi­cro­bio­me com­pa­ny that is now set­ting its sights on cre­at­ing a drug de­vel­op­ment arm.

Launched 6 years ago from its base in the Bay Area, uBio­me has launched a pair of con­sumer tests that can do at-home tests on your gut or the STDs that women face, like chlamy­dia and gon­or­rhea. Now the com­pa­ny has raised $83 mil­lion from ven­ture back­ers — led by OS Fund — in a new dri­ve to join the pack de­vel­op­ing new mi­cro­bio­me ther­a­pies. That’s been a fast-grow­ing field in re­cent times.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN